SEC Form 4 · accession 0001209191-18-019618
Biohaven Pharmaceutical Holding Co Ltd. · BHVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Berman
Officer — Chief Medical Officer
Period of report
Mar 12, 2018
Accepted (ET)
Mar 14, 2018 · 5:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001689813
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF2 | Mar 12, 2018 | S | 6,410 | $30.06 | D | 590,590 | I | By Berman Family Trust 2013 |
| Common SharesF3 | Mar 12, 2018 | S | 590 | $30.68 | D | 590,000 | I | By Berman Family Trust 2013 |
| Common SharesF2 | Mar 12, 2018 | S | 25,640 | $30.06 | D | 406,360 | I | By Berman Marital Trust 2013 |
| Common SharesF3 | Mar 12, 2018 | S | 2,360 | $30.68 | D | 404,000 | I | By Berman Marital Trust 2013 |
| Common Shares | holding | — | — | — | 50 | I | Owned by spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.58 - $30.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 - $30.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.